Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine Feb 16, 2019 05:14PM
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study Sep 11, 2018 08:28AM
Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab) Jun 4, 2018 08:00AM
Merck KGaA, Pfizer (PFE) Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced NSCLC Feb 15, 2018 08:45AM
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer Feb 15, 2018 08:30AM


Dec 21, 2017 01:00PM FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
Nov 28, 2017 08:10AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer
Nov 28, 2017 08:04AM Merck (MRK) and Pfizer (PFE) Announce Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer Did Not Meet Primary Endpoint
Nov 28, 2017 08:00AM Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer
Sep 21, 2017 06:23AM Merck KGaA, Pfizer (PFE) Report European Commission Approval for Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Sep 21, 2017 03:13AM European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Sep 11, 2017 06:57AM Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance
Jul 21, 2017 07:52AM Merck KGaA, Pfizer (PFE) Report EMA's CHMP Issued Positive Opinion for Avelumab for Treatment of mMCC
Jul 21, 2017 07:50AM EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
May 17, 2017 05:00PM Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
Oct 31, 2016 03:00AM European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Feb 22, 2016 11:30AM Merck Puts Spotlight on Women's Health and Well-being